SIRT6 activator 12q|cas:2601734-99-8|西域试剂

SIRT6 activator 12q,98.01%

产品编号：Bellancom-148712| CAS NO：2601734-99-8| 分子式：C₃₁H₂₂N₂O₂| 分子量：454.52

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-148712	￥1200.00	杭州北京（现货）
Bellancom-148712	￥2000.00	杭州北京（现货）
Bellancom-148712	￥3900.00	杭州北京（现货）
Bellancom-148712	￥6000.00	杭州北京（现货）
Bellancom-148712	￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SIRT6 activator 12q

产品介绍

SIRT6 activator 12q 是有效的、选择性的和具有口服活性的 SIRT6 激活剂，对 SIRT1、SIRT2、SIRT3、SIRT5、SIRT6 的 IC₅₀ 值分别为 171.20、>200、>200、>200、0.58 μM。SIRT6 activator 12q 抑制细胞生长和迁移。SIRT6 activator 12q 诱导细胞凋亡 (Apoptosis) 和细胞周期停滞在 G2 期。SIRT6 activator 12q 显示出抗癌活性。

生物活性

SIRT6 activator 12q is potent, selective and orally active SIRT6 activator with IC₅₀ values of 171.20, >200, >200, >200, 0.58 μM for SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, respectively. SIRT6 activator 12q inhibits cell growth and migration. SIRT6 activator 12q induces Apoptosis and cell cycle arrest at G2 phase. SIRT6 activator 12q shows anticancer activity.

体外研究

SIRT6 activator 12q (2.5, 5, 10 µM; 14, 18 days) 以剂量依赖性方式抑制 PANC-1、BXPC-3、MIAPaCa-2 和 AsPC-1 细胞的集落形成.
SIRT6 activator 12q (10, 25, 50 µM; 48 h) 以剂量依赖性方式诱导细胞凋亡和细胞周期停滞在 G2 期。
SIRT6 activator 12q (12.5, 25, 50 µM; 48 h) 以剂量依赖性方式降低 PANC-1 和 BXPC-3 细胞中 H3K9ac、H3K18ac 和 H3K56ac 的蛋白表达。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	PANC-1, BXPC-3, MIAPaCa-2, and AsPC-1 cells
Concentration:	0-100 µM
Incubation Time:	72 h
Result:	Showed antiproliferative activity with IC₅₀s of 4.43, 8.27, 7.10, 9.66 µM for PANC-1, BXPC-3, MIAPaCa-2, and AsPC-1 cells, respectively.

Cell Cycle Analysis

Cell Line:	PANC-1, BXPC-3 cells
Concentration:	10, 25, 50 µM
Incubation Time:	48 h
Result:	Induced cell cycle arrest at G2 phase in a dose-dependent manner.

Apoptosis Analysis

Cell Line:	PANC-1, BXPC-3 cells
Concentration:	10, 25, 50 µM
Incubation Time:	48 h
Result:	Induced apoptosis by increased Annexin V+ populations in a concentration-dependent manner.

Western Blot Analysis

Cell Line:	PANC-1, BXPC-3 cells
Concentration:	12.5, 25, 50 µM
Incubation Time:	72 h
Result:	Decreased the protein levels of H3K9ac, H3K18ac, and H3K56ac in PANC-1 and BXPC-3 cells in a dose-dependent manner.

体内研究
(In Vivo)

SIRT6 activator 12q (100, 150 mg/kg; p.o.; daily for 30 days) 以剂量依赖性方式抑制小鼠肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c female nude mice (human pancreatic tumor xenograft model of PANC-1)
Dosage:	100, 150 mg/kg
Administration:	P.o.; daily for 30 days
Result:	Inhibited tumer growth in a dose-dependent manner, and a tumor inhibition rate of 90.25% at a dose of 150 mg/kg.

体内研究

SIRT6 activator 12q (100, 150 mg/kg; p.o.; daily for 30 days) 以剂量依赖性方式抑制小鼠肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c female nude mice (human pancreatic tumor xenograft model of PANC-1)
Dosage:	100, 150 mg/kg
Administration:	P.o.; daily for 30 days
Result:	Inhibited tumer growth in a dose-dependent manner, and a tumor inhibition rate of 90.25% at a dose of 150 mg/kg.

体内研究

SIRT6 activator 12q (100, 150 mg/kg; p.o.; daily for 30 days) 以剂量依赖性方式抑制小鼠肿瘤生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c female nude mice (human pancreatic tumor xenograft model of PANC-1)
Dosage:	100, 150 mg/kg
Administration:	P.o.; daily for 30 days
Result:	Inhibited tumer growth in a dose-dependent manner, and a tumor inhibition rate of 90.25% at a dose of 150 mg/kg.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (55.00 mM; ultrasonic and warming and heat to 70°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2001 mL	11.0006 mL	22.0012 mL
5 mM	0.4400 mL	2.2001 mL	4.4002 mL
10 mM	0.2200 mL	1.1001 mL	2.2001 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (2.75 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.75 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。